Suppr超能文献

急性心肌梗死发病时肌酐及肌酐清除率与后续死亡率的关系。

Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality.

作者信息

Gibson C Michael, Pinto Duane S, Murphy Sabina A, Morrow David A, Hobbach Hans Peter, Wiviott Stephen D, Giugliano Robert P, Cannon Christopher P, Antman Elliott M, Braunwald Eugene

机构信息

TIMI Study Chairman's Office, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.

出版信息

J Am Coll Cardiol. 2003 Nov 5;42(9):1535-43. doi: 10.1016/j.jacc.2003.06.001.

Abstract

OBJECTIVES

We hypothesized that impaired renal function would also be associated with poorer clinical outcomes among patients with ST-segment elevation myocardial infarction (STEMI) treated with fibrinolysis.

BACKGROUND

Previous studies have demonstrated that impaired renal function is associated with poorer clinical outcomes in the setting of unstable angina and non-STEMI and after percutaneous coronary intervention.

METHODS

Data were drawn from the Thrombolysis In Myocardial Infarction (TIMI)-10, TIMI-14, and Intravenous nPA for the Treatment of Infarcting Myocardium Early (InTIME-II) trials.

RESULTS

Within each TIMI risk score (TRS) for STEMI category (0 to 2, 3 to 4, >/=5), 30-day mortality increased stepwise among patients with normal (creatinine [Cr] </=1.2 mg/dl), mildly (Cr >1.2 to 2 mg/dl), and severely (Cr >2.0 mg/dl) impaired renal function (p < 0.001) and in patients with normal (creatinine clearance [CrCl] >/=90 ml/min), mildly (60 to <90 ml/min), moderately (30 to <60 ml/min), and severely (<30 ml/min) impaired CrCl (p < 0.001). Impaired renal function was associated with increased mortality after adjusting for previously identified correlates of mortality (using Cr: odds ratio [OR] for mild impairment 1.52, 95% confidence interval [CI] 1.30 to 1.77, p < 0.001; OR for severe impairment 3.73, 95% CI 2.55 to 5.45, p < 0.001; using CrCl: OR for mild impairment 1.38, 95% CI 1.10 to 1.73, p = 0.006; OR for moderate impairment 2.06, 95% CI 1.59 to 2.66, p < 0.001; OR for severe impairment 3.81, 95% CI 2.57 to 5.65, p < 0.001).

CONCLUSIONS

In the setting of STEMI, elevated Cr and/or impaired CrCl on presentation is associated with increased mortality, independent of other conventional risk factors and TRS. This association does not appear to be mediated by reduced fibrinolytic efficacy among patients with impaired renal function or by the presence of congestive heart failure on presentation.

摘要

目的

我们推测,在接受纤溶治疗的ST段抬高型心肌梗死(STEMI)患者中,肾功能受损也会与更差的临床结局相关。

背景

既往研究表明,在不稳定型心绞痛、非STEMI以及经皮冠状动脉介入治疗后,肾功能受损与更差的临床结局相关。

方法

数据取自心肌梗死溶栓治疗(TIMI)-10、TIMI-14以及早期心肌梗死静脉注射nPA治疗(InTIME-II)试验。

结果

在STEMI各TIMI风险评分(TRS)类别(0至2、3至4、≥5)中,肾功能正常(肌酐[Cr]≤1.2mg/dl)、轻度受损(Cr>1.2至2mg/dl)和重度受损(Cr>2.0mg/dl)的患者,以及肌酐清除率(CrCl)正常(CrCl≥90ml/min)、轻度受损(60至<90ml/min)、中度受损(30至<60ml/min)和重度受损(<30ml/min)的患者,30天死亡率均呈逐步上升趋势(p<0.001)。在校正先前确定的死亡相关因素后,肾功能受损与死亡率增加相关(使用Cr:轻度受损的比值比[OR]为1.52,95%置信区间[CI]为1.30至1.77,p<0.001;重度受损的OR为3.73,95%CI为2.55至5.45,p<0.001;使用CrCl:轻度受损的OR为1.38,95%CI为1.10至1.73,p = 0.006;中度受损的OR为2.06,95%CI为1.59至2.66,p<0.001;重度受损的OR为3.81,95%CI为2.57至5.65,p<0.001)。

结论

在STEMI患者中,就诊时Cr升高和/或CrCl受损与死亡率增加相关,独立于其他传统危险因素和TRS。这种关联似乎并非由肾功能受损患者纤溶疗效降低或就诊时存在充血性心力衰竭介导。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验